Developing and testing a patient information booklet for thrombolysis used in acute stroke

International Journal of Pharmacy Practice

Volumn 18, Issue 6, 2010, Pages 362-369

  Knapp, Peter ^a   Wanklyn, Peter ^b   Raynor, D K ^a   Waxman, Robin ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

consent; information; readability; thrombolysis

Indexed keywords

ALTEPLASE;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; PATIENT INFORMATION; PERFORMANCE; PRIORITY JOURNAL; READING; STROKE; WRITING;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; CEREBRAL HEMORRHAGE; COMPREHENSION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFORMED CONSENT; MALE; MIDDLE AGED; PAMPHLETS; PATIENT EDUCATION AS TOPIC; PILOT PROJECTS; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 78649267807     PISSN: 09617671     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7174.2010.00060.x     Document Type: Article

References (32)

1. Ley P,. Communication in the clinical setting. Br J Orthod 1973; 1: 173 - 177.
2. Wilson M, et al. Customers' recall of information given in community pharmacies. Int J Pharm Pract 1992; 1: 52 - 59.
3. Grime J, et al. The role and value of written information for patients about individual medicines: a systematic review. Health Expect 2007; 10: 286 - 298.
4. O'Connor AM, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2009; 2: CD001431.
5. Department of Health. Better Information, Better Choices, Better Health: Putting Information at the Centre of Health. London: Department of Health, 2004.
6. Raynor DK, Dickinson D,. Key principles to guide development of consumer medicines information - content analysis of information design texts. Ann Pharmacother 2009; 43: 700 - 706.
7. Edwards A, et al. Explaining risks: turning numerical data into meaningful pictures. Br Med J 2002; 324: 827 - 830.
8. Larkin JH, Simon HA,. Why a diagram is (sometimes) worth ten thousand words. Cogn Sci 1987; 11: 65 - 99.
9. Yin HS, et al. Randomized controlled trial of a pictogram-based intervention to reduce liquid medication dosing errors and improve adherence among caregivers of young children. Arch Paediatr Adolesc Med 2008; 162: 814 - 822.
10. Mullet K, Sano D,. Designing Visual Interfaces: Communication Oriented Techniques. Englewood Cliffs, NJ: Prentice Hall, 1995.
11. Ancker JS, et al. Design features of graphs in health risk communication: a systematic review. J. Am Med Informatics Assoc 2006; 13: 608 - 618.
12. Paling J,. Strategies to help patients understand risks. Br Med J 2003; 327: 745 - 748.
13. Price HC, et al. Use of focus groups to develop methods to communicate cardiovascular disease risk and potential for risk reduction to people with type 2 diabetes. Fam Pract 2009; 26: 351 - 358.
14. McLaughlin GH,. SMOG Grading - a new readability formula. J Read 1969; 12: 639 - 646.
15. Sless D, Wiseman R,. Writing about Medicines for People. Canberra: Department of Health and Human Sciences, 1997.
16. European Commission. Draft Guideline on the Readability of the Label and Package Leaflet of Medicinal Products for Human Use. 2006. (accessed 30 July 2010).
17. Willis GB,. Cognitive Interviewing: A Tool for Improving Questionnaire Design. London: Sage, 2005.
18. The ATLANTIS, ECASS, and NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768 - 774.
19. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581 - 1587.
20. Hacke W, et al. for the ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study. JAMA 1995; 274: 1017 - 1025.
21. Hacke W, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous Alteplase in acute ischaemic stroke. Lancet 1998; 352: 1245 - 1251.
22. Clark WM, et al. The rt-PA (Alteplase) 0- to 6-hour acute stroke trial, part A (A0267g): results of a doubleblind, placebo-controlled, multicenter study. Stroke 2000; 31: 811 - 816.
23. Clark WM, et al. for the Thrombolytic Therapy in Acute Ischemic Stroke Study Investigators. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS study - a randomized controlled trial. JAMA 1999; 282: 2019 - 2026.
24. Hacke W, et al. for the ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischaemic stroke. N Engl J Med 2008; 359: 1317 - 1329.
25. Wahlgren N, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST). Lancet 2007; 369: 826.
26. National Institute for Health and Clinical Excellence. Alteplase for the treatment of acute ischaemic stroke. London: National Institute for Health and Clinical Excellence, 2007. (accessed 14 December 2009).
27. Department of Health. National Stroke Strategy. London: Department of Health, 2007.
28. Rosenbaum JR, et al. Informed consent for thrombolytic therapy for patients with acute ischemic stroke treated in routine clinical practice. Stroke 2004; 35: e353 - e355.
29. Lentz L, De Jong M,. The evaluation of text quality: expert-focused and reader-focused methods compared. IEEE Trans Prof Comm 1997; 40: 224 - 233.
30. Knapp P, et al. Performance-based readability testing of participant information for a Phase 3 IVF trial. Trials 2009; 10: 79.
31. Koops L, Lindley RI,. Thrombolysis for acute ischaemic stroke: consumer involvement in design of new randomised controlled trial. Br Med J 2002; 325: 415.
32. Juniper EF, et al. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992; 47: 76 - 83.